Actinium Pharmaceuticals
ATNM
67 hedge funds and large institutions have $52.8M invested in Actinium Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 4 closing their positions.
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
149% more call options, than puts
Call options by funds: $3.23M | Put options by funds: $1.3M
80% more capital invested
Capital invested by funds: $29.3M → $52.8M (+$23.5M)
14% more funds holding
Funds holding: 59 → 67 (+8)
3.29% more ownership
Funds ownership: 21.01% → 24.3% (+3.3%)
0% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
+$1.26M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$980K |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$643K |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$599K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$528K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$305K |
| 2 |
Morgan Stanley
New York
|
-$186K |
| 3 |
Barclays
London,
United Kingdom
|
-$118K |
| 4 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$72.6K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$67.3K |
ATNM Hedge Fund Activity: Q1 2024 in Review
67 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q1 2024, worth a combined $52.8M — up 80% from $29.3M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ATNM positions and 4 closed out — a net gain of 9 holders — while 18 added to existing stakes and 18 trimmed.
The largest buyer was Verition Fund Management, opening a new position worth an estimated $1.26M. The largest seller was Bank of New York Mellon, cutting an estimated $305K.
- 67 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q1 2024, up from 59 in Q4 2023.
- Funds reported $52.8M of Actinium Pharmaceuticals stock for Q1 2024, up 80% quarter-over-quarter.
- 13 funds opened new Actinium Pharmaceuticals positions in Q1 2024 and 4 closed out, a net change of +9 holders.
- The largest Actinium Pharmaceuticals buyer in Q1 2024 was Verition Fund Management, an estimated $1.26M added.
- The largest Actinium Pharmaceuticals seller in Q1 2024 was Bank of New York Mellon, an estimated $305K sold.
Based on aggregated 13F filings for Q1 2024.